Dexlansoprazole for the treatment of esophagitis and GERD

Drugs of Today

Volumn 46, Issue 2, 2010, Pages 75-80

  Davies, Shelley L ^a  

^a UNIVERSITY OF WORCESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CLOPIDOGREL; DEXLANSOPRAZOLE; DIAZEPAM; ESOMEPRAZOLE; GASTRIN; KAPIDEX; LANSOPRAZOLE; MOXIFLOXACIN; NORDAZEPAM; OMEPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; TAK 390 MR; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; NON EROSIVE REFLUX DISEASE; PLASMA CONCENTRATION-TIME CURVE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH ACID SECRETION; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WOUND HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS;

EID: 77953596698     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.2.1437714     Document Type: Article

References (31)

1. FDA Approves Kapidex. http://www.drugs.com/newdrugs/fda-approves-kapidex- dexlansoprazole-gerd-1250.html, accessed December 17 2009.
2. Heartburn, Gastroesophageal Reflux (GER), and Gastroesophageal Reflux Disease (GERD). http://digestive.niddk.nih.gov/ddiseases/pubs/gerd/, -accessed December 17 2009.
3. Positional Therapy Offers Treatment Alternative. http://www.gerd.net/, accessed December 17 2009.
4. Yuan Y, Hunt R.H. Evolving issues in the management of reflux disease? Curr Opin Gastroenterol 2009, 25(4): 342-51.
5. Metz, D.C., Vakily, M., Dixit, T., Mulford, D. Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009, 29(9): 928-37.
6. Official Kapidex Website, http://www.kapidex.com/Default.aspx, accessed December 17 2009.
7. Efficacy of dexlansoprazole MR on heartburn control in subjects previously receiving twice daily proton pump inhibitor therapy (NCT00847808). www.ClinicalTrials.gov, accessed December 2 2009.
8. A study of the effects of multiple doses of lansoprazole, dexlansoprazole, omeprazole or esomeprazole on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects (NCT00942175). www.ClinicalTrials.gov, accessed December 1 2009.
9. Zhang, W., Wu, J.-T., Atkinson, S. Pharmacokinetic (PK), pharmacodynamic (PD), and safety evaluation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole (LAN) in healthy subjects. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1194.
10. Wu, J., Vakily, M., Witt, G., Mulford, D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 15.
11. Vakily, M., Zhang, W., Wu, J., Atkinson, S.N., Mulford, D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009, 25(3): 627-38.
12. Lee, R.D., Vakily, M., Mulford, D., Wu, J., Atkinson, S.N. Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - Evidence for dosing flexibility. Aliment Pharmacol Ther 2009, 29(8): 824-33.
13. Lee, R.D., Vakily, M., Wu, J., Atkinson, S. The effect and timing of food on the pharmacokinetics and pharmacodynamics of TAK-390MR (modified release): Evidence for dosing flexibility. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 78.
14. Lee, R.D., Mulford, D., Wu, J., Atkinson, S.N. The effect of time-of-day dosing of TAK-390MR on the pharmacokinetics and pharmacodynamics of TAK-390: Evidence for dosing flexibility with this dual delayed release proton pump inhibitor. Dig Dis Week (May 30-June 4, Chicago) 2009, Abst M1892.
15. Vakily, M., Wu, J.T., Atkinson, S., Mulford, D. Population pharmacokinetics (PK) of TAK-390MR in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). 37th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 14-16, Philadelphia) 2008, Abst 22.
16. Lee, R.D., Wu, J., Vakily, M., Mulford, D. Effect of hepatic impairment on the pharmacokinetics of TAK-390MR (modified release). Clin Pharmacol Ther 2008, 83(Suppl. 1): Abst PIII-75.
17. Vakily, M., Wu, J., Gunawardhana, L., Mulford, D. Assessment of potential drug interactions between modified-release TAK-390 (TAK-390MR) and warfarin in healthy adult subjects. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 9-11, San Francisco) 2007, Abst 37.
18. Vakily, M., Wu, J., Mulford, D. Evaluation of the effects of modified-release TAK-390 (TAK-390MR) on the pharmacokinetics of theophylline in healthy adult subjects. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 9-11, San Francisco) 2007, Abst 36.
19. Lee, R.D., Vakily, M., Wu, J. Effect of modified-release TAK-390 (TAK-390MR) on the pharmacokinetics of diazepam and its major metabolite in healthy adult subjects. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 9-11, San Francisco) 2007, Abst 34.
20. Lee, R.D., Vakily, M., Wu, J. Evaluation of the drug interaction potential of modified-release TAK-390 (TAK-390MR) and phenytoin in healthy adult subjects. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 9-11, San Francisco) 2007, Abst 35.
21. Metz, D.C., Howden, C.W., Perez, M.C., Larsen, L, O'Neil, J., Atkinson, S.N. Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009, 29(7): 742-54.
22. Dabholkar, A., Yu, P., Paris, M. Long-term safety of TAK-390MR, a PPI with a novel dual delayed release formulation, in GERD patients. Am J Gastroenterol 2008, 103(Suppl. 1): Abst 14.
23. Howden, C., Larsen, L., Palmer, R., Perez, C. Placebo-controlled trial of 2 doses of TAK-390MR, a PPI with novel dual delayed release technology, as maintenance treatment for patients with healed erosive esophagitis (EE). Am J Gastroenterol 2008, 103(Suppl. 1): Abst 13.
24. Metz, D.C., Howden, C.W., Perez, M.C. et al. TAK-390MR, a proton pump inhibitor with a novel dual delayed release formulation, maintains healing and controls heartburn in GERD patients with healed erosive esophagitis. Gastroenterology 2008, 134(4, Suppl. 1): Abst S1074.
25. Fass, R., Chey, W.D., Zakko, S.F., Andhivarothai, N., Palmer, R.N., Perez, M.C., Atkinson, S.N. Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009, 29(12): 1261-72.
26. Mody, R., Larsen, L., Perez, M., Pilmer, B., Dabbous, O. TAK-390MR maintains relief of gastroesophageal reflux disease (GERD) symptoms and improvements in quality of life in GERD patients with healed erosive esophagitis. Am J Gastroenterol 2008, 103(Suppl. 1): Abst 57.
27. Sharma, P., Shaheen, N.J., Perez, M.C., Pilmer, B.L., Lee, M., Atkinson, S.N., Peura, D. Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009,29(7): 731-41.
28. Sharma, P., Shaheen, N.J., Perez, M.C. et al. TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE): Data from two randomized controlled trials. Gastroenterology 2008, 134(4, Suppl. 1): Abst S1073.
29. Shaheen, N., Peura, D., Perez, M.C., Pilmer, B., Witt, G., Sharma, P. Impact of baseline LA grade on healing of erosive esophagitis (EE) following treatment with TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release formulation, compared with lansoprazole (LAN). Am J Gastroenterol 2008, 103(Suppl. 1): Abst 24.
30. Vakily, M., Wu, J., Atkinson, S. Effect of single oral doses (90 and 300mg) of TAK-390MR on QT intervals. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PI-43.
31. Zhang, W., Wu, J., Atkinson, S. Effects of TAK-390MR on plasma gastrin levels in healthy adults. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PI-44